Hepatology

Findings suggest the current emphasis on targeting inflammation to mitigate fibrosis in MASLD may be incorrect, citing the minimal impact of LBP function loss on fibrosis.

Using NHANES data, researchers calculated AGILE 3 + and AGILE 4 scores to determine the prevalence of advanced fibrosis and cirrhosis in patients with MASLD in the US.

Positive topline results from the phase 2 SPRING trial highlight CM-101’s anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in primary sclerosing cholangitis.

The expanded label includes use in patients with PFIC 12 months of age and older as well as a higher concentration formulation.

The nomogram was constructed using independent risk factors for early cirrhosis and demonstrated greater diagnostic accuracy than current noninvasive fibrosis tests.

The homogenous genotyping test combines allele-specific tailed primers with SYBR-Green to facilitate fast and accurate detection of PI*S and PI*Z alleles of SERPINA1.

Primary care patients with MASLD who received a prescription for moderate- and high-intensity statins had a lower risk of progressing to a high-risk FIB-4 score.

The analysis of NHANES data found individuals with viral hepatitis and NAFLD as well as lower income and no college education were at a greater risk of mortality.

The cross-sectional analysis found Medicaid nonexpansion status, fibrosis, and sobriety restrictions negatively impacted annual rates of DAA prescription fills.

Findings highlight an increased risk of diabetes, MASLD, and cardiovascular disease in patients with PCOS, with risk varying by PCOS phenotype.

An analysis of data from the NV-HOPE study calls attention to lower rates of HBV and HCV screening among low-income US veterans versus the general US veteran population.

Refusal of hospital-administered birth doses of the hepatitis B vaccine declined in Washington, DC, from 2017-2022 despite pandemic-related disruptions to other childhood vaccines.

Findings underscore the importance of HCC screening adherence in patients with HCV-related cirrhosis who achieve HCV cure for improving overall survival.

Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.

Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

Shiffman reviews some of the key findings from AHFIRM, explaining important considerations for interpreting the results and potential reasons for regional differences in the data.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

Shiffman describes the current treatment landscape for alcohol-associated hepatitis and what larsucosterol might offer for these patients.

The marketing authorization makes the Xpert HCV test and GeneXpert Xpress System the first point-of-care test for diagnosing HCV.

Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.

Ross-Driscoll explains how disparities in the liver transplant process begin prior to waitlisting and how findings from her research on referral and evaluation may inform interventions.

A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.

Gish explains recent developments in the treatment of PBC, highlighting the FDA approval of elafibranor, the anticipated decision for seladelpar, and the growing role of combination therapy.

In this video segment, Palak and Trivedi discuss strategies for improving the management of patients in real-world settings given recent advances in therapies and pathophysiology.

In this video segment, Palak and Trivedi dive into a discussion on emerging therapies and therapeutic targets for management of PBC.

In this video segment, Palak and Trivedi break down their perspectives on the current state of unmet need in primary biliary cholangitis from a clinical and patient perspective.

In this video segment, Palak and Trivedi discuss the approval of elafibranor and other therapies that could receive approval for management of primary biliary cholangitis in the near future.